2011年至2022年期间,日本儿童疫苗的估计覆盖率:2012年至2022年期间,日本儿童疫苗的估计覆盖率:2011年至2022年期间,日本儿童疫苗的估计覆盖率:2011年至2022年期间,日本儿童疫苗的估计覆盖率:2021年至202
Jun Miyata1, Shingo Fukuma2,3
1Department of Island and Community Medicine, Nagasaki University Graduate School of Biomedical Sciences.
Environmental health and preventive medicine
|October 8, 2025
概括
日本 日本 日本 日本 日本.
科学领域:
- 免疫学 免疫学 免疫学
- 公共卫生 公共卫生
- 流行病学 流行病学
背景情况:
- 在日本,全国自愿接种疫苗覆盖率数据缺乏.
- 公共补贴对疫苗接种率的影响需要进一步调查.
- 了解疫苗覆盖率对于公共卫生战略至关重要.
研究的目的:
- 为了估计日本全国自愿接种疫苗的覆盖率.
- 将自愿接种疫苗的覆盖率与国家免疫计划 (NIP) 包含的疫苗进行比较.
- 研究公共补贴对疫苗接种率的有效性.
主要方法:
- 从2011年10月到2022年3月使用全国每月的疫苗市场数据 (罗塔病毒,Hib,DTaP-IPV,)
- 估计的接种人数,以计算疫苗覆盖率.
- 使用布兰德-阿尔特曼分析,将市场衍生的覆盖率与NIP疫苗的WHO/联合国儿童基金会估计进行了比较.
主要成果:
- 对Haemophilus influenzae type b (Hib) 和DTaP-IPV疫苗的市场数据估计略高于世卫组织/联合国儿童基金会的估计.
- 在国家补贴之前,罗塔病毒疫苗的覆盖率显著增加,到2020年达到0.9.
- 在2012年和2014年,Hib和DTaP-IPV疫苗分别实现了完全覆盖 (1.0);疹疫苗覆盖率呈现逐步增加.
结论:
- 日本的疫苗覆盖率估计,虽然可能被高估,但作为一个有价值的替代品.
- 自愿接种轮状病毒和疹疫苗的覆盖率显示出日益增长的趋势.
- 分享有关日本补贴影响的调查结果,可以为国际疫苗政策提供信息.
更多相关视频
09:37Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
2.2K
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
13.9K
相关概念视频
Vaccinations
51.2K
Overview
51.2K
Pharmacokinetics in Pediatric Patients: Drug Distribution
252
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
252
Prevalence and Incidence
1.5K
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
1.5K
Drug Dosing: Infants and Children
253
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
253
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
242
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
242
Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
